New Drug Design Strategy Targets Cancer's Most Stubborn Mutation
Researchers have identified why some experimental drugs work 60 times better than others at fixing a broken tumor-suppressor protein found in many cancers. The discovery rewrites the rulebook for drug design: effectiveness depends not just on binding strength, but on whether molecules can rewire the protein's internal communication networks—a principle that could accelerate development of treatments for drug-resistant tumors.
Originaltitel: Mechanistic Insights into the Allosteric Regulation of P53 Y220C by Small-Molecule Stabilizers
<p>The p53 Y220C mutation is a recurrent hotspot alteration that induces local unfolding and long-range functional disruption, compromising its tumor suppressor activity. While small-molecule stabilizers targeting this mutation have shown therapeutic promise, their underlying allosteric regulatory mechanisms remain poorly defined. Here, we investigate two p53 Y220C stabilizers with near-identical scaffolds but over 60-fold difference in activity, serving as a model to dissect the structural basis of differential efficacy. Through microsecond-scale molecular dynamics simulations and residue interaction network analysis, we reveal that the more active compound not only engages the mutation-induced cavity but also restores long-range cooperative networks and DNA-binding interfaces by rewiring key allosteric communication pathways disrupted by the mutation. Our results uncover a multilayered allosteric rescue mechanism involving dynamic pocket engagement, hydrophobic core reconstruction, and intramolecular signal reactivation. These findings move beyond conventional binding-affinity explanations and highlight the importance of network-level conformational regulation in mutant p53 rescue. This work establishes a mechanistic foundation for rational stabilizer design, proposing a new strategy centered on allosteric network restoration and mutation-adaptable anchoring. It offers broader implications for targeting conformationally unstable transcription factors previously considered "undruggable".</p>